Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-02-28
Schrödinger, Inc.
Schrödinger develops and licenses computational chemistry software for molecular discovery and also earns revenue from drug discovery collaborations and select internal programs.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A hosted transition could unlock a software re-rate
The setup is a visibility-driven re-rating: if the hosted shift holds retention and the platform adds new monetizable modules, value can compound faster than revenue. The main debate is whether insourcing and tool consolidation cap pricing before profitability proof arrives.

Analysis

Thesis
If the hosted/ratable transition improves revenue visibility without retention damage, SDGR can re-rate from a “hybrid biotech” to a governed, API-embedded discovery operating layer—capturing expanding in‑silico budgets while keeping therapeutics upside mostly partner-funded.
Last Economy Alignment
Cheaper compute makes simulation+AI discovery more valuable, and SDGR’s control points are workflow embedding (API/LiveDesign) plus enterprise governance; the main risk is large customers insourcing and turning the stack into a swappable module.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
6.5x (from 5 most recent analyses)
Reasoning
The upside is less about a single breakthrough drug and more about becoming the default execution-and-governance layer for automated discovery: deeper API embed, more hosted deployments, and more attach of new modules (e.g., predictive tox) should steadily expand wallet share inside top accounts. If management hits its 2028 profitability objective and hosted becomes the majority contract type, the market can underwrite SDGR on higher-quality recurring software economics (plus collaboration optionality), driving multiple expansion alongside revenue growth.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The binding risks are (1) customer-controlled adoption/renewal timing during the hosted transition, (2) competitive substitution from in-house and alternative discovery stacks that can cap pricing power, and (3) execution risk in converting better visibility into durable profitability by 2028; drug-discovery milestones can help, but they are outside SDGR’s control.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.51
They’re positioned to be the “trusted execution layer” for automated molecular discovery because their workflows embed via an API and team system-of-record software. The risk is that big customers replicate the stack internally and make the tools interchangeable before the hosted transition creates durable visibility.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$24.33
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case